UNSPSC 51332502: Azabuperone

This classification denotes an antipsychotic agent with the molecular formula C17H23FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9P043590EX chemically known as 4'-fluoro-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)butyrophenone but generally known as azabuperone, which bears US NIH Compound Identifier 18484. European Medicines Agency schedules Azabuperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05623MIG.

UNSPSC 51332502 Azabuperone is a Commodity code that, based on recent state and local opportunities, encompasses pharmaceutical products including prescription medications, naloxone, and over-the-counter health products distributed through government health systems and cooperative purchasing alliances. State and local procurement activity under this code spans county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. Seminole County, Florida, for example, recently issued an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to support community health initiatives. The Texas Health and Human Services Commission posted an RFI to explore vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions.

Recent activity concentrates in Texas, Minnesota, and Florida. Seminole County's IFB (IFB60459723LAS, due July 26, 2023) requires unit pricing for naloxone and drug deactivation systems with quarterly deliveries, E-Verify compliance, and workers' compensation and liability insurance; the contract carries a two-year initial term with one-year renewal options and potential FEMA funding. The Texas HHS Commission's RFI (HHS0017013, response deadline April 3, 2026) seeks vendor experience with direct contracting for self-insured employers and health plans using negotiated net pricing models and value-based agreements—an exploratory phase before formal RFP issuance. MMCAP's RFP (S1070000015802, due March 26, 2026) requires manufacturers to supply generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with NDC compliance, cGMP certification, DSCSA compliance, and pricing competitiveness weighted at 75 percent of evaluation; products must reach market by May 15, 2026, with contracts effective July 1, 2026, and carry a 3 percent administrative fee on all purchases.